| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Golimumab |
| Brand | (Simponi®) |
| Indication | For the treatment of moderate to severe rheumatoid arthritis. |
| Assessment Process | |
| Rapid review commissioned | 20/11/2009 |
| Rapid review completed | 11/05/2010 |
| Rapid review outcome | Reimbursement recommended following price review, June 2010. |
The review group did not consider golimumab cost-effective at the submitted price in May 2010.
Following a price reduction the review group now consider golimumab to be cost-effective. June 2010.